In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia

Summary.  Factors that reduce the intracellular concentration of triphosphorylated cytarabine (ara‐CTP), the active form of cytarabine (ara‐C), may induce chemoresistance in acute myeloid leukaemia (AML) patients. These factors include reduced influx of ara‐C by the hENT1 transporter, reduced phosphorylation by deoxycytidine kinase (dCK), and increased degradation by high Km cytoplasmic 5′‐nucleotidase (5NT) and/or cytidine deaminase (CDD). Increased levels of DNA polymerase α (DNA POL) and reduced levels of topoisomerase I (TOPO I) and topoisomerase II (TOPO II) have also been detected in ara‐C‐resistant cell lines. To determine whether these factors are implicated in clinical ara‐C resistance, we analysed the expression of these parameters at diagnosis, using reverse transcription polymerase chain reaction, in the blast cells of 123 AML patients treated with ara‐C. At diagnosis, hENT1, dCK, CDD, 5NT, TOPO I, TOPO II, DNA POL and MDR1 were expressed in 83%, 22%, 7%, 37%, 59%, 37%, 39% and 16% of patients respectively. In univariate analysis, patients with expression of 5NT or DNA POL at diagnosis had significantly shorter disease‐free survival (DFS). In multivariate analysis, DNA POL positivity and hENT1 deficiency were related to a shorter DFS. In univariate analysis, patients with 5NT‐positive blasts had significantly shorter overall survival (OS). In multivariate analysis, shorter OS was related to DNA POL positivity. These results suggest that expression of DNA POL, 5NT and hENT1 at diagnosis may be resistance mechanisms to ara‐C in AML patients.

[1]  J. Mackey,et al.  Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. , 2001, Blood.

[2]  J. Mackey,et al.  Nucleoside analogues: mechanisms of drug resistance and reversal strategies , 2001, Leukemia.

[3]  R. Hickey,et al.  Differential inhibition of the human cell DNA replication complex-associated DNA polymerases by the antimetabolite 1-beta-D-arabinofuranosylcytosine triphosphate (ara-CTP). , 2000, Biochemical pharmacology.

[4]  R. Hickey,et al.  Ara-C differentially affects multiprotein forms of human cell DNA polymerase , 2000, Cancer Chemotherapy and Pharmacology.

[5]  R. Hickey,et al.  Ara-C affects formation of cancer cell DNA synthesome replication intermediates , 2000, Cancer Chemotherapy and Pharmacology.

[6]  N. Osheroff,et al.  Cytosine Arabinoside Lesions Are Position-specific Topoisomerase II Poisons and Stimulate DNA Cleavage Mediated by the Human Type II Enzymes* , 1999, The Journal of Biological Chemistry.

[7]  G. Peters,et al.  Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562 , 1999, British journal of haematology.

[8]  J. Zalcberg,et al.  Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. , 1999, Blood.

[9]  P. Reichard,et al.  Human high-Km 5'-nucleotidase effects of overexpression of the cloned cDNA in cultured human cells. , 1999, European journal of biochemistry.

[10]  M. Baccarani,et al.  P‐glycoprotein, lung resistance‐related protein and multidrug resistance associated protein in de novo acute non‐lymphocytic leukaemias: biological and clinical implications , 1999, British journal of haematology.

[11]  S. Seeber,et al.  Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia , 1998, British journal of haematology.

[12]  R. Herrmann,et al.  Five putative drug resistance parameters (MDR1/P‐glycoprotein, MDR‐associated protein, glutathione‐S‐transferase, bcl‐2 and topoisomerase IIα) in 57 newly diagnosed acute myeloid leukaemias , 1997 .

[13]  C. Cass,et al.  Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells , 1997, Neuropharmacology.

[14]  W. Hiddemann,et al.  Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy , 1997, Blood.

[15]  A. J. Chapman,et al.  Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  B. Goz,et al.  A possible role for topoisomerase II in cell death and N-phosphonoacetyl-L-aspartate-resistance frequency and its enhancement by 1-beta-D-arabinofuranosyl cytosine and 5-fluoro-2'-deoxyuridine. , 1997, Mutation research.

[17]  A. Paterson,et al.  Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. , 1997, Blood.

[18]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.

[19]  R. Herrmann,et al.  Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIalpha) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK). , 1997, European journal of haematology.

[20]  S. Seeber,et al.  Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. , 1996, Leukemia.

[21]  T. Grogan,et al.  Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. , 1996, Blood.

[22]  M. Tribalto,et al.  Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. , 1996, Blood.

[23]  F. Perrino,et al.  The Effects of Cytosine Arabinoside on RNA-primed DNA Synthesis by DNA Polymerase α-Primase (*) , 1995, The Journal of Biological Chemistry.

[24]  D. Hipfner,et al.  Characterization of the Mr 190,000 Multidrug Resistance Protein (MRP) in Drug-selected and Transfected Human Tumor Cells , 1995 .

[25]  D. Hipfner,et al.  Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cell. , 1995, Cancer research.

[26]  R. Pieters,et al.  Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  J. Laliberté,et al.  Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA. , 1994, Cancer research.

[28]  L. Zwelling,et al.  Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. , 1994, Blood.

[29]  M. Slovak,et al.  Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. , 1993, Cancer research.

[30]  F. Perrino,et al.  Incorporation of cytosine arabinoside monophosphate into DNA at internucleotide linkages by human DNA polymerase alpha. , 1992, The Journal of biological chemistry.

[31]  H. Hori,et al.  Decreased DNA polymerase sensitivity to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in P388 murine leukemic cells resistant to vincristine. , 1991, Leukemia research.

[32]  J. Wiley,et al.  Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells. , 1990, Leukemia research.

[33]  E. Estey,et al.  Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. , 1987, Leukemia.

[34]  D. Richel,et al.  Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia. , 1987, Seminars in oncology.

[35]  S. Akman,et al.  Metabolism of ara-C by blast cells from patients with ANLL. , 1986, Blood.

[36]  J. Minowada,et al.  Inhibition of DNA polymerase alpha from leukemic and normal human cells by partially thiolated human deoxyribonucleic acids. , 1985, Cancer biochemistry biophysics.

[37]  Jan Liliemark,et al.  Relationship of 1-β-d-Arabinofuranosylcytosine in Plasma to 1-β-d-Arabinofuranosylcytosine 5′-Triphosphate Levels in Leukemic Cells during Treatment with High-Dose 1-β-d-Arabinofuranosylcytosine , 1985 .

[38]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[39]  L. R. Finch,et al.  Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. , 1985, The Journal of clinical investigation.

[40]  W. Plunkett,et al.  Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine. , 1985, Cancer research.

[41]  K. Bhalla,et al.  Isolation and Characterization of a Deoxycytidine Kinase-deficient Human Promyelocyte Leukemic Cell Line Highly Resistant to 1-β-D- Arabinofuranosylcytosine , 1984 .

[42]  K. Bhalla,et al.  Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine. , 1984, Cancer research.

[43]  Masao Tanaka,et al.  Altered Sensitivity to 1-β-d-Arabinofuranosylcytosine 5′-Triphosphate of DNA Polymerase α from Leukemic Blasts of Acute Lymphoblastic Leukemia , 1982 .

[44]  M. Tanaka,et al.  Altered sensitivity to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate of DNA polymerase alpha from leukemic blasts of acute lymphoblastic leukemia. , 1982, Cancer research.

[45]  D. Kufe,et al.  Correlation of cytotoxicity with incorporation of ara-C into DNA. , 1980, The Journal of biological chemistry.

[46]  A. Matsukage,et al.  Inhibitory effects of 9-beta-D-arabinofuranosylguanine 5'-triphosphate and 9-beta-D-arabinofuranosyladenine 5'-triphosphate on DNA polymerases from murine cells and oncornavirus. , 1979, Cancer research.

[47]  A. Matsukage,et al.  Inhibitory effect of 1-beta-D-arabinofuranosylthymine 5'-triphosphate and 1-beta-D-arabinofuranosylcytosine 5'-triphosphate on DNA polymerases from murine cells and oncornavirus. , 1978, Cancer research.

[48]  S. Yoshida,et al.  Inhibition of DNA polymerase-α and -β of calf thymus by 1-β-d-arabinofuranosylcytosine-5′-triphosphate , 1977 .

[49]  S. Yoshida,et al.  Inhibition of DNA polymerase-alpha and -beta of calf thymus by 1-beta-D-arabinofuranosylcytosine-5'-triphosphate. , 1977, Biochimica et biophysica acta.

[50]  C. N. Coleman,et al.  Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. , 1975, Blood.

[51]  M. Tattersall,et al.  Mechanisms of Resistance of Human Acute Leukaemia Cells to Cytosine Arabinoside , 1974, British journal of haematology.

[52]  C. D. Steuart,et al.  Cytidine deaminase and the development of resistance to arabinosyl cytosine. , 1971, Nature: New biology.